ChAd155载体狂犬病疫苗与灭活纯化鸡胚细胞狂犬病疫苗在健康成人中的安全性和免疫原性比较
该首次人体1期随机双盲剂量递增试验在健康成人中比较ChAd155-RG与已上市灭活疫苗RabAvert。ChAd155-RG安全性可耐受,但仅接受RabAvert或两剂高剂量ChAd155-RG的组别达到100%血清阳转,且RabAvert组血清保护最持久;作者认为载体预存免疫可能影响免疫应答。
要点
- ChAd155-RG组轻中度全身反应原性及短暂淋巴细胞和中性粒细胞减少较RabAvert组更常见。
- 仅RabAvert组和两剂高剂量ChAd155-RG组达到100%血清阳转,RabAvert组血清保护最持久。
- 多数受试者存在抗载体预存抗体,基线及接种后抗载体抗体滴度与狂犬病病毒中和抗体滴度呈负相关。
核心结论
- 在该1期试验中,新型猿腺病毒载体狂犬病疫苗安全可耐受,但产生的狂犬病病毒中和抗体滴度低于标准灭活狂犬病疫苗且持久性更差,作者认为可能与预存抗载体免疫有关。
研究设计与样本
- 首次人体、1期、随机、双盲、剂量递增试验,在健康成人中比较ChAd155-RG与已上市灭活疫苗RabAvert。
- 受试者接受RabAvert标准剂量,或ChAd155-RG低剂量免疫1次,或高剂量免疫1次或2次。
主要发现
- ChAd155-RG受试者中轻中度全身反应原性及短暂淋巴细胞减少和中性粒细胞减少较RabAvert受试者更常见。
- 未报告血栓事件或严重不良事件。
- 仅接受RabAvert或两剂高剂量ChAd155-RG的组别达到100%血清阳转,RabAvert组血清保护最持久。
- 多数受试者存在抗载体预存抗体,且被ChAd155-RG增强。
- 基线及接种后抗载体抗体滴度与接种后狂犬病病毒中和抗体滴度呈负相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies is a zoonotic viral encephalitis that is endemic in many countries and confers a high mortality. Licensed vaccines require several doses to ensure efficacy. To investigate a logistically favorable approach, we assessed the safety and immunogenicity of ChAd155-RG, a novel investigational rabies vaccine using a replication-defective chimpanzee adenovirus vector. METHODS: We conducted a first-in-human, phase 1, randomized, double-blind, dose-escalation trial comparing ChAd155-RG with a licensed inactivated vaccine (RabAvert) in healthy adults. Participants received either RabAvert at standard dosing or ChAd155-RG at a low dose for one immunization or a high dose for one or two immunizations. To assess safety, we evaluated reactogenicity, unsolicited adverse events, and thrombotic events. To measure immunogenicity, we measured rabies viral neutralizing antibody (VNA) titers and anti-ChAd155 neutralizing antibodies. RESULTS: Mild to moderate systemic reactogenicity and transient lymphopenia and neutropenia were more common among recipients of ChAd155-RG compared with those who received RabAvert. No thrombotic events or serious adverse events were reported. Only the groups receiving RabAvert or two doses of high-dose ChAd155-RG achieved 100 % seroconversion, and seroprotection was most durable in the RabAvert group. Most participants had preexisting anti-vector antibodies, which were boosted by ChAd155-RG. Baseline and post-vaccination anti-vector antibody titers were negatively associated with post-vaccination rabies VNA titers. CONCLUSIONS: In this phase 1 clinical trial, a novel rabies vaccine using a simian adenovirus vector was safe and tolerable, but generated lower, less durable rabies VNA titers than a standard inactivated rabies virus vaccine, which may be due to preexisting, anti-vector immunity.
引用
- Phadke VK, Gromer DJ, Rebolledo PA, et al. Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults. Vaccine. 2024. PMID: 39418686. doi:10.1016/j.vaccine.2024.126441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。